On June 19, 2023, it was revealed that ETF Managers Group LLC had purchased a new position in shares of Ultragenyx Pharmaceutical Inc. This move represents the latest development in the ongoing saga of the biopharmaceutical company’s financial fortunes and prospects for commercial success.
As a company focused on rare and ultra-rare genetic diseases, Ultragenyx Pharmaceutical has been at the forefront of cutting-edge research and development in this field for years. Its biologic products, including Crysvita, Mepsevii, Dojolvi, and Evkeeza, have all shown great promise in clinical trials and are poised to become major players in the pharmaceutical industry as a whole.
However, as evidenced by the company’s most recent quarterly earnings report from May 4th, there are still significant challenges ahead. Ultragenyx Pharmaceutical reported an EPS of ($2.33) for the quarter – significantly lower than analysts’ expectations – and also had a negative return on equity and negative net margin.
Despite these obstacles, many experts predict that Ultragenyx Pharmaceutical will rebound strongly in the coming months and years. The company’s dedication to developing novel treatments for rare diseases has won it widespread acclaim within the medical community, while its robust pipeline of potential new therapies offers investors considerable reason for optimism.
In short: while there is no question that Ultragenyx Pharmaceutical faces significant challenges moving forward, there is also a great deal of hope and excitement surrounding its future prospects. As with any biopharmaceutical company operating in this rapidly-evolving industry landscape, it remains to be seen what lies ahead – but one thing is certain: we will all be watching closely to see what happens next.
[bs_slider_forecast ticker=”RARE”]
Institutional Investors Increase Stake in Ultragenyx Pharmaceutical
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”RARE” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]Ultragenyx Pharmaceutical, a biopharmaceutical company with a focus on rare and ultra-rare genetic diseases, has seen its stake grow among institutional investors in recent months. Notable increases in holdings include Lazard Asset Management LLC’s 36.6% growth during the first quarter, Quadrant Capital Group LLC’s 111.4% increase in holdings, Signaturefd LLC’s rise of 143.7%, Harbor Capital Advisors Inc.’s boost of 26.1%, and Echo Street Capital Management LLC’s purchase of a new position during the first quarter worth $234,000. As of June 19th, approximately 96.56% of Ultragenyx Pharmaceutical’s stock is owned by institutional investors and hedge funds.
Shares for Ultragenyx Pharmaceutical opened at $48.28 on Monday with a historical low of $33.36 and high of $68.68 over the past year. The biopharmaceutical firm operates throughout North America, Latin America, Japan, Europe, and internationally focusing on biologic products such as Crysvita (burosumab), Mepsevii enzyme replacement therapy treatment for Mucopolysaccharidosis VII patients, Dojolvi treating long-chain fatty acid oxidation disorders and Evkeeza (evinacumab) targeting homozygous familial hypercholesterolemia.
In other Ultragenyx Pharmaceutical news on June 8th this year Corazon (Corsee) D Sanders sold 1485 shares valued at a total consideration of $76,700.25 while Karah Herdman Parschauer sold 4,378 shares valued around $197k during May period. Following these transactions Corazon D Sanders holds around 9,570 shares while executive vice president Karah Herdman Parschauer still owns some 51k-plus Ultragenyx share.
The investments haven’t gone unnoticed by analysts, either. A number of firms have issued reports on Ultragenyx Pharmaceutical in recent weeks. Evercore ISI upgraded the company from an ‘in-line’ to an ‘outperform’ rating and adjusted its price target from $60 to $80 per share. Meanwhile, Cantor Fitzgerald issued the firm an “overweight” rating and set a price objective at $114.
Overall, three investment analysts rated Ultragenyx Pharmaceutical with a hold rating while 11 gave the company a buy rating resulting in an average Bloomberg.com consensus of “Moderate Buy.”
